Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy vs Placebo + Chemotherapy in Gastric or EGJ Adenocarcinoma
NCT05180734Phase 3Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Feb 2022; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05180734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180734.